Healthy Adults Needed for Beryllium Disease Study

Trial Objective

The Immunoregulatory Role of Alveolar Macrophages in Chronic Beryllium DiseaseChronic beryllium disease (CBD) is caused by inhaling beryllium dust and fumes into the lungs. People with exposure can develop a response to beryllium similar to an allergy which can lead to scars in the lungs and breathing problems.

The goal of this study is to understand how certain white blood cells called macrophages function in the development of CBD. By collecting lung and blood samples from healthy adults, our researchers can learn more about the cells involved in the development of scarring lung diseases and ultimately target new treatment therapies.

Enrollment

New enrollment for this trial is temporarily paused

Who Can Participate

Healthy, nonsmoking adults with no prior history of respiratory or autoimmune disease who are able to undergo a blood draw and a bronchoscopy.

Age: 18-80    Gender: Any Gender


Estimated Time Commitment

5 hours over 2 visits

During the first visit, participants give consent and receive physical exam. Second visit includes bronchoalveolar lavage and blood draw. The second visit will last approximately four hours.



Payment & Reimbursement  

Payment: Provided

Travel Reimbursement: Not Available

Trial Contact

For more information, contact:

Peggy Mroz

Peggy Mroz
303.398.1730

Request More Information

Trial Location

National Jewish Main Campus, Denver, CO

Trial Sponsors

National Institutes of Health

Co-Investigators


Request More Information

Due to concerns around COVID-19 and our focus on helping to meet this momentous challenge, we have temporarily paused enrollment for all trials requiring an in-person visit. Please feel free to request additional information about any of the trials we have posted and we will get back to you when enrollment resumes. For more resources and information on COVID-19 please visit our special coronavirus website at www.njhealth.org/coronavirus.


*
*
*
*